Eldorado research project

To date, there are approximately 39 million people living with HIV (PLHIV) worldwide. Since 2018, WHO recommends dolutegravir as preferred first-line antiretroviral therapy (ART) for all PLHIV. While dolutegravir is a highly effective and widely prescribed antiretroviral, emerging evidence suggests it is associated with metabolic side effects such as obesity, diabetes, and hypertension. ELDORADO is an international, multicenter, clinical research project that aims at evaluating the toxicity of dolutegravir-based antiretroviral treatment and investigates doravirine as a potentially safer and equally virologically effective first-line alternative for PLHIV. ELDORADO includes a randomized clinical trial, conducted across six countries on four continents: Cameroon, Côte d’Ivoire, Mozambique, Brazil, Thailand, and France, that will compare dolutegravir and doravirine in terms of: . Virologic efficacy . Safety (including metabolic, cardiac, and hepatic outcomes) . Mental health and quality of life The project also includes a modelling work package that will build further evidence on health impact and cost-effectiveness of using the different doravirine and dolutegravir for ART using cohort and trial data including that from the ELDORADO trial. Beyond clinical research and modelling, ELDORADO also focuses on capacity-building, supporting young investigators, clinicians, researchers, and community engagement across participating countries. This interdisciplinary project aims to generate high-quality evidence to inform global and national HIV treatment guidelines. ELDORADO is supported by the Global Health EDCTP3 Joint Undertaking, Inserm-ANRS MIE, and MSD.